Legitimacy checklist
How to tell if a GLP-1 telehealth provider is legitimate.
A five-signal buyer checklist for the storefronts that look the same at the headline — state medical-board licensure, 503A vs 503B pharmacy accreditation, prescriber credentials, transparent pricing, and real patient support — so the offer you pay holds up after the first charge clears.
1. State medical-board licensure.
Every legitimate GLP-1 telehealth provider names the clinician who will write your prescription — a physician (MD or DO), a nurse practitioner (NP), or a physician assistant (PA) — and the state that licenses them, before you pay. You verify the name the same way you would verify a doctor at an in-person clinic: pull up that state’s online medical-board lookup, paste in the clinician’s name, and confirm the license is active, unencumbered, and covers the address where the telehealth visit will occur. If the storefront cannot name the clinician at checkout, that is not a disclosure choice — it is the first of the five signals to walk away on.
This is the same licensing thread that runs through our provider verification guide: the clinician must be licensed in the state where you physically sit during the visit, not the state where the company is incorporated. Cross-state licensing is one of the most common — and least visible — reasons a checkout flow quietly fails after the consultation fee has already been charged.
2. 503A vs 503B pharmacy accreditation.
The second signal is the pharmacy that actually fills the vial. Whatever the prescription is for, the pharmacy must be licensed in your state and must sit in one of two federal categories. A 503A traditional compounding pharmacy prepares the drug for an individual patient on receipt of a valid prescription — dose, sterility, and purity are the pharmacy’s own responsibility, which is why the cost per patient is generally higher. A 503B outsourcing facility operates under stricter, FDA-style manufacturing standards and can produce batches in advance, which is why those offers tend to land lower on the price ladder. Both are legal compounding pathways; neither is an FDA approval route.
Run the pharmacy name past the National Association of Boards of Pharmacy (NABP) accredited-pharmacy list and your own state board of pharmacy before you pay. If the storefront names a different pharmacy in checkout than during the consult, names no pharmacy at all, or quietly blends a compounded product into brand pricing — that is the second signal to walk. Brand-name semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) ship from the manufacturer’s own FDA-approved supply chain; any storefront offering “Ozempic” at compounded prices is not selling what the label says, and is rarely a legitimate operation.
3. Prescriber credentials.
Beyond being licensed, the prescribing clinician should be an MD, DO, NP, or PA with an active, unencumbered license in your state at the time of the visit — not the state where the company is incorporated. Cross-state prescribing without that state license is the most common — and least visible — failure mode in this market; the prescription is not valid for your state’s pharmacy to fill, and the consultation fee stays charged while the medication does not arrive. The clinician’s name should sit on your account page before any charge, not after.
A telehealth storefront that rotates clinicians between visits, refuses to name the prescriber until after payment, or staffs exclusively with out-of-state clinicians for an in-state customer base is not running a clinical practice — it is running a fulfillment operation. The license is the second of the five signals, and it sits in exactly the same place the pharmacy accreditation sits: before the first charge, named plainly, verifiable in a public database, and stable across visits.
4. Transparent pricing.
The fourth signal is whether the offer tells you the full price before you give it your card. The headline price is the consultation fee, the medication fee, or the first month’s bundle — never all three. A legitimate provider quotes the all-in monthly cost over the first six months on a single line: consult, dose, pharmacy fulfillment, shipping, and the titration step-ups that hit at months two and three when the clinician moves you to the therapeutic dose. If the offer only shows the starter month, ask for the price at the actual maintenance dose — the figure you will pay for most of the year.
Run that number against the other offers on the same assumptions. The providers index lists each storefront with its stated price; the head-to-head comparison lays each one’s all-in monthly cost side by side under transparent assumptions so the “flat $99” offers stop looking flat once the titration math is in. Two offers can quote the same starter month and produce wildly different six-month totals because of dose tier and bundle structure; transparency is what surfaces that gap before you pay.
5. Real patient support.
The fifth signal is what happens after the prescription ships. A legitimate GLP-1 program names a clinician for ongoing follow-up, supports license-verifiable asynchronous messaging (a clinical inbox routed to a named prescriber, not a no-reply address), sets out a clear escalation path for side effects — what to do at the first sign of dehydration, persistent nausea, or a missed dose — and names a pharmacy support contact in case a refill slips or a vial arrives warm. None of these are premium add-ons; each one is part of running a clinical practice online.
A storefront that lists a single shared inbox, no on-staff clinician for follow-up, and a scripted response template for side effects is not running a clinical practice. GLP-1 therapy is titrated and tolerability-driven; the people who run it have to be reachable after the consult closes. The side-by-side comparison includes the support model alongside price and credentials — run the same five checks here too, because support is part of the offer, not a separate decision made after the first charge clears.